파이프라인
다양한 타겟에 대한 임상/전임상 파이프라인
바이오사이토젠은 환자의 수요를 만족시키는 혁신적인 항체 신약 개발을 위하여, 항암, 자가면역질환, 대사질환, 감염질환 등의 다양한 질병 영역에서 독자적이며 혁신적인 신약개발 능력을 활용하여 단일클론항체, 이중특이성항체, ADC 등을 포함한 십여개의 연구개발중인 파이프라인을 보유하고 있습니다. 강력한 임상개발팀과 풍부한 임상자원을 바탕으로, 잠재력있는 파이프라인의 개발을 가속화하여 신약의 임상 개발 과정을 앞당기고 있습니다.
Therapeutic Area
Products
Target
Partner
Molecular Format
Indication
Status
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Oncology
BCG003
TNFR2
Dragonboatbio
Monoclonal Antibody
Solid Tumors
BCG001
B7-H3
Mabworks
Monoclonal Antibody
Solid Tumors
BCG008
SIGLEC15
UNDISCLOSED
Monoclonal Antibody
Solid Tumors
BCG002
CD24
UNDISCLOSED
Monoclonal Antibody
Solid Tumors
BCG005
CCR8
LiberoThera
Monoclonal Antibody
Solid Tumors
BCG007
AMHR2
UNDISCLOSED
Monoclonal Antibody
Solid Tumors
Infectious Diseases
Oncology
YH003
More
Target：
CD40
Partner：
Molecular Format：
Monoclonal antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH001
More
Target：
CTLA-4
Partner：
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH002
More
Target：
OX40
Partner：
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH004
More
Target：
4-1BB
Partner：
Molecular Format：
Monoclonal antibody
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH005
More
Target：
Claudin18.2- ADC
Partner：
Remegen
Molecular Format：
ADC
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH008
More
Target：
PD-1 x CD40
Partner：
Molecular Format：
Bispecific antibody
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH006
More
Target：
CTLA-4 x OX40
Partner：
Molecular Format：
Bispecific antibody
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH010
More
Target：
PD-L1 x IL12
Partner：
Molecular Format：
Bispecific antibody
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH011
More
Target：
PD-L1 x cytokine
Partner：
GeneQuantum
Molecular Format：
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH012
More
Target：
HER2 x TROP2
Partner：
Molecular Format：
Bispecific ADC
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH013
More
Target：
EGFR x MET
Partner：
Molecular Format：
Bispecific ADC
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG003
More
Target：
TNFR2
Partner：
Dragonboatbio
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG001
More
Target：
B7-H3
Partner：
Mabworks
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG008
More
Target：
SIGLEC15
Partner：
UNDISCLOSED
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG002
More
Target：
CD24
Partner：
UNDISCLOSED
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG005
More
Target：
CCR8
Partner：
LiberoThera
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG007
More
Target：
AMHR2
Partner：
UNDISCLOSED
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Infectious Diseases
YH009
More
Target：
RSV
Partner：
Molecular Format：
Monoclonal antibody
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
바이오사이토젠은 이미 전 세계의 여러 제약회사들과 완전 인간 항체 생산 마우스 플랫폼의 사용 계약과 항체신약 개발의 파트너쉽을 체결하였습니다. 파트너쉽에 대해 더 알아보시려면 아래를 클릭해주세요.
파이프라인과 관련된 합작 문의 : bd@eucure.com
합작연구개발파이프라인과 관련된 합작 문의 : bd@eucure.com
+86-010-56967680
Copyright © 2021 Biocytogen. All Rights Reserved
Powered by Fractal-technology